search
Back to results

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Primary Purpose

Myositis, Dermatomyositis, Polymyositis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Rituximab
Placebo
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myositis focused on measuring rituximab, myositis, dermatomyositis, polymyositis, refractory, Juvenile Dermatomyositis

Eligibility Criteria

5 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults with definite or probable dermatomyositis or polymyositis and pediatric patients five years of age and over with definite or probable juvenile dermatomyositis (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e., first symptom of myositis or dermatomyositis rash) is less 18 years of age Refractory myositis, defined by intolerance to or inadequate response to corticosteroids plus an adequate regime of at least one other immunosuppressive agent. Intolerance is defined as side effects that require discontinuation of the medication or an underlying condition that precludes further use of the medication. Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test) score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the following criteria: An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. OR If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at least 3 abnormal core set measures. Background therapy with at least 1 non-corticosteroid immunosuppressive agent at a stable dose for at least 6 weeks prior to screening Able and willing to complete self-report questionnaires. Parents of pediatric participants will be required to complete the questionnaires on behalf of their children. Willing to use acceptable forms of contraception for the duration of the study for patients of reproductive potential. Parent willing to provide informed consent, if applicable Willing to forgo immunization with a live vaccine for the duration of the study Exclusion Criteria: Drug-induced myositis. Patients who have myositis or myopathic syndromes caused by taking medications known to induce myositis-like syndromes, including but not limited to statin agents, fibric acid derivatives, colchicine, and hydroxychloroquine. Juvenile polymyositis Inclusion body myositis Cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the diagnosis of cancer. Patients with basal or squamous cell skin cancer or carcinoma in situ of the cervix are not excluded, if it has been at least 5 years since excision. Myositis in overlap with another connective tissue disease that may preclude the accurate assessment of a treatment response Live viral vaccine within 4 weeks prior to study entry Any joint disease or other musculoskeletal condition that may interfere with muscle strength testing Known hypersensitivity to mouse proteins Any concomitant or life-threatening non-myositis illness that, in the opinion of the investigator, may interfere with the study Known or suspected history of drug or alcohol abuse within the last 6 months prior to study entry, as determined by medical record or patient interview Anticipated poor compliance with study requirements Participation in another clinical trial within 30 days prior to screening Any history or evidence of any severe illness or other condition that, in the opinion of the investigator, may interfere with the study Previously received rituximab Evidence of prior infection with hepatitis B or hepatitis C virus Initiation of an exercise program within 4 weeks of screening OR initiation of an exercise program during the study Consumed any creatine-containing, over-the-counter products in the form of dietary supplements 30 days prior to screening visit and for the duration of the study

Sites / Locations

  • University of Alabama Arthritis Intervention Program (Adult Site)
  • Phoenix Neurological Associates, LTD (Adult Site)
  • Cedars-Sinai Medical Center (Adult Site)
  • Stanford University (Adult Site)
  • Stanford University (Pediatric Site)
  • University of Miami School of Medicine (Adult Site)
  • Miami Children's Hospital (Pediatric Site)
  • University of Kansas Medical Center (Adult Site)
  • Kentucky Clinic (Adult Site)
  • National Institute of Health (Adult Site)
  • National Institute of Health (Pediatric Site)
  • Children's Hospital of Boston (Pediatric Site)
  • Beth Israel Deaconess Medical Center (Adult Site)
  • University of Michigan Health System (Adult Site)
  • Michigan State University (Adult and Pediatric Site)
  • Mayo Clinic (Adult Site)
  • Mayo Clinic (Pediatric Site)
  • North Shore Long Island Jewish Health System (Adult Site)
  • Hospital for Special Surgery (Adult Site)
  • Duke University Medical Center (Pediatric Site)
  • Cincinnati's Children's Hospital (Pediatric Site)
  • Children's Hospital of Philadelphia (Pediatric Site)
  • University of Pennsylvania (Adult Site)
  • Children's Hospital of Pittsburgh (Pediatric Site)
  • University of Pittsburgh / UPMC (Adult Site)
  • University of Texas Southwestern Medical Center (Adult)
  • Medical College of Wisconsin / Froedtert Memorial Luthern Hospital (Adult Site)
  • IWK Health Centre
  • Hospital for Sick Children (Pediatric Site)
  • Institute of Rheumatology
  • Karolinska Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Adult Study Group 1

Adult Study Group 2

Adult Study Group 3

Adult Study Group 4

JDM Study Group 1

JDM Study Group 2

Arm Description

Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)

Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)

Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)

Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)

Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)

Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)

Outcomes

Primary Outcome Measures

Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients
The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures. Core Set Measures Included: Manual Muscle Testing (MMT)- Muscle Strength Physician Global Disease Activity VAS Score Health Assessment Questionnaire Index Score - Physical Function Patient Global Assessment of Disease Activity VAS score Extramuscular Activity - Myositis Disease Activity Assessment Tool 2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)

Secondary Outcome Measures

Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8
The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures. Core Set Measures Included: Manual Muscle Testing (MMT)- Muscle Strength Physician Global Disease Activity VAS Score Health Assessment Questionnaire Index Score - Physical Function Patient Global Assessment of Disease Activity VAS score Extramuscular Activity - Myositis Disease Activity Assessment Tool 2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)
20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])
Number of participants with a 20% improvement in MMT over baseline on two consecutive time points.

Full Information

First Posted
March 21, 2005
Last Updated
March 3, 2015
Sponsor
University of Pittsburgh
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Genentech, Inc., Biogen
search

1. Study Identification

Unique Protocol Identification Number
NCT00106184
Brief Title
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Official Title
Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Genentech, Inc., Biogen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rituximab is a man-made antibody used to treat certain types of cancer. This study will determine whether rituximab is an effective treatment for adult and pediatric patients with dermatomyositis or polymyositis. Study hypotheses: 1) The time to improvement in Group A patients (receiving rituximab first) will occur significantly earlier than in Group B patients (receiving rituximab later). 2) The proportion of patients improved at Week 8 of the treatment phase will be significantly greater in Group A than in Group B.
Detailed Description
Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed against the CD20 (cluster of differentiation antigen 20) antigen found on the surface of B-lymphocytes and is known to deplete B cells when administered intravenously. It is approved to treat non-Hodgkin's lymphoma. Rituximab has been used for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and immune-mediated hematologic disorders. It has also been studied and used in small numbers of patients with myositis. This study will evaluate the efficacy of rituximab in treating refractory adult and pediatric patients with dermatomyositis and adult polymyositis. A patient's participation in this study will last approximately 45 weeks. At screening, participants will have a physical exam, muscle strength assessment, an electrocardiogram, and blood and urine collection; they will also be asked to complete several questionnaires. All participants will receive 2 infusions of rituximab and 2 infusions of placebo. Participants will be randomly assigned to one of two groups. Group A will receive rituximab at Weeks 0 and 1 and placebo at Weeks 8 and 9. Group B will receive placebo at Weeks 0 and 1 and rituximab at Weeks 8 and 9. Each infusion will be given on an outpatient basis over a minimum of approximately 5 hours' time. There will be a total of 14 study visits. All participants will visit the outpatient clinic at selected time points for muscle strength testing, a physical exam, disease activity measurements, and blood collection. During the study, participants will be monitored closely for improvement or worsening of their disease and for serious drug related side effects. Some participants will be asked if they are willing to undergo 2 muscle biopsy procedures, 1 prior to receiving study medication and 1 after receiving study medication, to determine the effects of rituximab on muscle tissue. If a participant is unable to locate a near-by clinical center, the adult and pediatric centers at the National Institute of Health located in Bethesda, Maryland have funds available to assist with travel costs. NIH SUB-STUDY: "Rituximab to Treat Dermatomyositis and Polymyositis" This study is currently recruiting patients. Sponsored by: National Institute of Environmental Health Sciences (NIEHS) Information provided by: National Institutes of Health Clinical Center (CC) Expected Total Enrollment: 30 Study start: October 2006 Location and Contact Information: Patient Recruitment and Public Liaison Office;(800) 411-1222; prpl@mail.cc.nih.gov; Phone: 1-866-411-1010 The NIH sub-study will take advantage of the multi-center core RIM trial to identify changes in gene expression patterns in muscle, skin, and peripheral blood and the imaging features and immunopathology of muscle, skin, and peripheral cells before (week 0) and after (week 16) therapy. These changes will also be correlated with the large number of clinical, laboratory, and research variables already planned to be collected in the core RIM Study. Furthermore, knowing specifically which gene expression patterns are altered in resistant patients before rituximab, and which are changed after rituximab therapy - in conjunction with flow cytometry of peripheral cells and immunopathology of the tissues - will help in understanding more about the pathogenesis of myositis and the possible contribution of B lymphocytes and their subsets. Patients with dermatomyositis and polymyositis who meet the inclusion/exclusion criteria for the core RIM trial may be eligible for this sub-study. The following procedures will be conducted in addition to the core RIM trial procedures during the 13 clinic visits over a period of 44 weeks: Weeks 0, 16: Muscle and skin biopsy (adult only). Small samples of muscle and skin tissue will be surgically removed for examination under a microscope. Weeks 0, 8, 16, 44: Skin evaluation and photography. The effect of the disease on the skin will be thoroughly evaluated and photographs of any rashes and of the skin around the nails will be taken. Weeks 0, 8, 16, 44: Magnetic resonance imaging (MRI). All participants will have MRI scans of the skin and of the muscle in the legs. Adults will also have an MRI to examine blood flow in the muscle.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Keywords
rituximab, myositis, dermatomyositis, polymyositis, refractory, Juvenile Dermatomyositis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adult Study Group 1
Arm Type
Experimental
Arm Description
Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Arm Title
Adult Study Group 2
Arm Type
Experimental
Arm Description
Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Arm Title
Adult Study Group 3
Arm Type
Experimental
Arm Description
Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Arm Title
Adult Study Group 4
Arm Type
Experimental
Arm Description
Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Arm Title
JDM Study Group 1
Arm Type
Experimental
Arm Description
Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
Arm Title
JDM Study Group 2
Arm Type
Experimental
Arm Description
Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
Intervention Type
Drug
Intervention Name(s)
Rituximab
Other Intervention Name(s)
Rituxan
Intervention Description
Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Treatment Group A: placebo infusion at Weeks 8 and 9 Treatment Group B: placebo infusion at Weeks 0 and 1
Primary Outcome Measure Information:
Title
Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients
Description
The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures. Core Set Measures Included: Manual Muscle Testing (MMT)- Muscle Strength Physician Global Disease Activity VAS Score Health Assessment Questionnaire Index Score - Physical Function Patient Global Assessment of Disease Activity VAS score Extramuscular Activity - Myositis Disease Activity Assessment Tool 2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)
Time Frame
Week 44 of treatment phase
Secondary Outcome Measure Information:
Title
Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8
Description
The Definition of Improvement for both adult and pediatric patients will be: 3 of any of the 6 core set measures improved by ≥ 20%, with no more than 2 of the core set measures worsening by ≥25% (worsening measure cannot include the MMT) at two consecutive visits. Of note, the MMT could not be one of the worsening measures. Core Set Measures Included: Manual Muscle Testing (MMT)- Muscle Strength Physician Global Disease Activity VAS Score Health Assessment Questionnaire Index Score - Physical Function Patient Global Assessment of Disease Activity VAS score Extramuscular Activity - Myositis Disease Activity Assessment Tool 2 or more elevated muscle enzymes (Aldolase, CK, AST, ALT, and LDH)
Time Frame
Week 8 of the treatment phase
Title
20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])
Description
Number of participants with a 20% improvement in MMT over baseline on two consecutive time points.
Time Frame
Week 44 of treatment phase

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults with definite or probable dermatomyositis or polymyositis and pediatric patients five years of age and over with definite or probable juvenile dermatomyositis (JDM) by Bohan and Peter criteria. Diagnosis of JDM based on an age of onset (i.e., first symptom of myositis or dermatomyositis rash) is less 18 years of age Refractory myositis, defined by intolerance to or inadequate response to corticosteroids plus an adequate regime of at least one other immunosuppressive agent. Intolerance is defined as side effects that require discontinuation of the medication or an underlying condition that precludes further use of the medication. Baseline manual muscle testing which is based on a maximum MMT-8 (Manual Muscle Test) score of 150:Adult subjects with dermatomyositis (DM) or polymyositis (PM) must have a score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. Subjects with a diagnosis of Juvenile Dermatomyositis (JDM) must meet either of the following criteria: An MMT-8 (Manual Muscle Test) score that is no greater than 125/150 in conjunction with 2 other abnormal core set measures. OR If MMT (Manual Muscle Test) score is greater than 125/150 the patient MUST meet at least 3 abnormal core set measures. Background therapy with at least 1 non-corticosteroid immunosuppressive agent at a stable dose for at least 6 weeks prior to screening Able and willing to complete self-report questionnaires. Parents of pediatric participants will be required to complete the questionnaires on behalf of their children. Willing to use acceptable forms of contraception for the duration of the study for patients of reproductive potential. Parent willing to provide informed consent, if applicable Willing to forgo immunization with a live vaccine for the duration of the study Exclusion Criteria: Drug-induced myositis. Patients who have myositis or myopathic syndromes caused by taking medications known to induce myositis-like syndromes, including but not limited to statin agents, fibric acid derivatives, colchicine, and hydroxychloroquine. Juvenile polymyositis Inclusion body myositis Cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the diagnosis of cancer. Patients with basal or squamous cell skin cancer or carcinoma in situ of the cervix are not excluded, if it has been at least 5 years since excision. Myositis in overlap with another connective tissue disease that may preclude the accurate assessment of a treatment response Live viral vaccine within 4 weeks prior to study entry Any joint disease or other musculoskeletal condition that may interfere with muscle strength testing Known hypersensitivity to mouse proteins Any concomitant or life-threatening non-myositis illness that, in the opinion of the investigator, may interfere with the study Known or suspected history of drug or alcohol abuse within the last 6 months prior to study entry, as determined by medical record or patient interview Anticipated poor compliance with study requirements Participation in another clinical trial within 30 days prior to screening Any history or evidence of any severe illness or other condition that, in the opinion of the investigator, may interfere with the study Previously received rituximab Evidence of prior infection with hepatitis B or hepatitis C virus Initiation of an exercise program within 4 weeks of screening OR initiation of an exercise program during the study Consumed any creatine-containing, over-the-counter products in the form of dietary supplements 30 days prior to screening visit and for the duration of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chester V. Oddis, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ann M. Reed, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama Arthritis Intervention Program (Adult Site)
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Phoenix Neurological Associates, LTD (Adult Site)
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Cedars-Sinai Medical Center (Adult Site)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Stanford University (Adult Site)
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Stanford University (Pediatric Site)
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
University of Miami School of Medicine (Adult Site)
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Miami Children's Hospital (Pediatric Site)
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
University of Kansas Medical Center (Adult Site)
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Kentucky Clinic (Adult Site)
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Facility Name
National Institute of Health (Adult Site)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Facility Name
National Institute of Health (Pediatric Site)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Facility Name
Children's Hospital of Boston (Pediatric Site)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Beth Israel Deaconess Medical Center (Adult Site)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
University of Michigan Health System (Adult Site)
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Michigan State University (Adult and Pediatric Site)
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Facility Name
Mayo Clinic (Adult Site)
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Mayo Clinic (Pediatric Site)
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
North Shore Long Island Jewish Health System (Adult Site)
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Facility Name
Hospital for Special Surgery (Adult Site)
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Duke University Medical Center (Pediatric Site)
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Cincinnati's Children's Hospital (Pediatric Site)
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Facility Name
Children's Hospital of Philadelphia (Pediatric Site)
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pennsylvania (Adult Site)
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Children's Hospital of Pittsburgh (Pediatric Site)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
University of Pittsburgh / UPMC (Adult Site)
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15261
Country
United States
Facility Name
University of Texas Southwestern Medical Center (Adult)
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-8884
Country
United States
Facility Name
Medical College of Wisconsin / Froedtert Memorial Luthern Hospital (Adult Site)
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
IWK Health Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3K 6R8
Country
Canada
Facility Name
Hospital for Sick Children (Pediatric Site)
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
Facility Name
Institute of Rheumatology
City
Prague
Country
Czech Republic
Facility Name
Karolinska Institute
City
Stockholm
Country
Sweden

12. IPD Sharing Statement

Citations:
PubMed Identifier
11377114
Citation
Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol. 2001 Jun;54(6):550-7. doi: 10.1016/s0895-4356(00)00357-7.
Results Reference
background
PubMed Identifier
15692974
Citation
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005 Feb;52(2):601-7. doi: 10.1002/art.20849.
Results Reference
background
PubMed Identifier
23124935
Citation
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.
Results Reference
result
Links:
URL
http://www.myositis.org
Description
Click here for the Myositis Association Web site
URL
http://clinicalstudies.info.nih.gov/cgi/wais/bold032001.pl?A_07-E-0012.html@myositis
Description
Click here for the NIH Clinical Center (sub-study)

Learn more about this trial

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

We'll reach out to this number within 24 hrs